Related Experiment Video
Updated: Jan 11, 2026
07:00
Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
10.0K
The Ozempic Generation: What the Interventional Radiologist Needs to Know About GLP-1 Agonists.
Suhail Wani1, Salam Findakly1, Tuan Phan1,2
1Department of Radiology, Alfred Health, Melbourne, Australia.
Journal of Medical Imaging and Radiation Oncology
|November 15, 2025
Summary
Glucagon-like peptide 1 receptor (GLP-1) agonists are increasingly used for weight loss, impacting diabetes management. Interventional Radiologists must understand these drugs for safe peri-procedural care.
Area of Science:
- Pharmacology
- Endocrinology
- Interventional Radiology
Background:
- Glucagon-like peptide 1 receptor (GLP-1) agonists were initially for type II diabetes.
- These agents are now pivotal in weight management, with rapidly expanding usage.
- Interventional Radiologists (IRs) will encounter more patients on these medications.
Purpose of the Study:
- To inform Interventional Radiologists about GLP-1 agonists.
- To highlight the implications of GLP-1 agonists for peri-procedural management in IR.
- To advocate for IR-specific guidance regarding these drugs.
Main Methods:
- Review of pharmacological effects of GLP-1 agonists.
- Analysis of peri-procedural considerations for IR procedures.
- Discussion of current literature and clinical practice.
Main Results:
- GLP-1 agonists affect fasting glucose and gastric emptying.
- These effects necessitate adjustments in peri-procedural care, especially with conscious sedation.
- Current IR practice may not adequately address GLP-1 agonist use.
Conclusions:
- IRs require updated knowledge on GLP-1 agonists.
- Adapting peri-procedural protocols is crucial for patient safety.
- Development of IR-specific guidelines is needed for managing patients on GLP-1 agonists.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
828
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
828
01:23Dipeptidyl Peptidase 4 Inhibitors
570
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
570
01:06Oral Hypoglycemic Agents: Glinides
577
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
577
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
568
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
568
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
511
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
511
01:15Hypoglycemia and Glucagon
787
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
787